STOCK TITAN
  1. Home
  2. News
  3. CLPT

ClearPoint Neuro Inc - CLPT STOCK NEWS

Welcome to our dedicated news page for ClearPoint Neuro (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on ClearPoint Neuro.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ClearPoint Neuro's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ClearPoint Neuro's position in the market.

News
ClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System
Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) has received 510(k) clearance for its SmartFrame OR™ Stereotactic System, marking a strategic shift into the operating room. The system, composed of the SmartFrame OR and ClearPointer™ Optical Navigation Wand, aims to provide precise navigation for neurological procedures without the need for MRI, expanding the company's reach to more hospitals and patients. Limited market release is set for the first half of 2024, with a full market release planned for the second half.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
clinical trial
-
News
ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue
Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) announced preliminary unaudited financial results for Q4 2023 and full year 2023. Q4 highlights include a 32% year-over-year increase in revenue to $6.8 million, a 76% increase in biologics and drug delivery revenue to $4.1 million, and a cash burn of $1.2 million. Full year 2023 saw a record revenue of $24 million, a 17% increase, and a 49% increase in biologics and drug delivery revenue to $13.6 million. The company estimates 2024 revenue to be between $28 million and $32 million, with several new product introductions planned. The CEO expressed optimism about the company's performance and future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.91%
Tags
none
-
News
ClearPoint Neuro Reports Third Quarter 2023 Results
Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) reports Q3 revenue of $5.8M, a 12% YoY increase, with biologics and drug delivery revenue growing 55% to $3.5M. Operational cash burn at $1.8M, the lowest since 2020. The company forecasts 2023 revenue between $23.0M and $25.0M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.71%
Tags
earnings
News
ClearPoint Neuro to Announce Third Quarter 2023 Results November 9, 2023
Rhea-AI Summary
ClearPoint Neuro, Inc. will release its 2023 third quarter financial results on November 9. Investors and analysts can participate in the live broadcast review or access the replay afterwards. The Company's Investor website will also have an online archive of the broadcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
earnings
-
News
ClearPoint Neuro Reports Second Quarter 2023 Results
Rhea-AI Summary
ClearPoint Neuro, Inc. reports a record quarterly revenue of $6.0 million, a 14% YoY increase. Biologics and drug delivery revenue increased by 40% YoY to $3.4 million. The company reaffirms its 2023 revenue outlook of $25.0 to $27.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
earnings
-
News
ClearPoint Neuro to Announce Second Quarter 2023 Results August 8, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
earnings
News
ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
none
-
News
ClearPoint Neuro to Present at the B. Riley Securities 2023 Institutional Investor Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences
-
News
ClearPoint Neuro Reports First Quarter 2023 Results
Rhea-AI Summary
ClearPoint Neuro reports Q1 2023 financial results, with quarterly revenue of $5.4 million, an 8% YoY increase. Biologics and drug delivery revenue increased by 24% YoY to $2.7 million. The company reaffirms its 2023 revenue outlook of $25.0 to $27.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
earnings
News
ClearPoint Neuro to Present Investigational Research and Showcase Novel Innovations at the 26th American Society of Gene & Cell Therapy Annual Meeting in Los Angeles
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
conferences
Stock CLPT logo
ClearPoint Neuro Inc

Nasdaq:CLPT

CLPT Rankings

#3968 Ranked by Market Cap
#4617 Ranked by Stock Gains
N/A Ranked by Dividends

CLPT Stock Data

157.27M
24.73M
7.6%
29.16%
4.72%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Solana Beach

About CLPT

we are a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or mri, guidance. since our inception in 1998, we have focused on research and product development in the field of interventional mri. from 1998 to 2002, we deployed significant resources to fund our efforts to develop the foundational capabilities for enabling mri-guided interventions and to build an intellectual property position. in 2003, our focus shifted to identifying and building out commercial applications for the technologies we developed in prior years. we have two product platforms. our clearpoint® system, which is in commercial use in the united states, is used to perform minimally invasive surgical procedures in the brain. our cleartrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. bot